How to Avoid Common FAERS Submission Errors and FDA Validation Failures Understanding the nuances of US pharmacovigilance requirements, including proper submission to the FDA Adverse Event Reporting System (FAERS), is critical for pharmaceutical companies seeking to ensure compliance and maintain marketability of their products. Errors in FAERS submissions can lead to significant regulatory consequences, including warning letters and detrimental impacts on public health. This tutorial serves as a step-by-step guide for pharmaceutical professionals to effectively navigate FAERS reporting requirements, minimize errors, and enhance compliance with 21 CFR safety reporting guidelines. Understanding FAERS and Its Importance in Pharmacovigilance The FDA Adverse…

Using Dashboards and KPIs to Monitor US Pharmacovigilance Performance Pharmacovigilance (PV) is an essential aspect of drug safety that involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Adhering to US pharmacovigilance requirements, including the management of FAERS reporting, REMS implementation, and other pertinent regulations is critical for pharmaceutical companies. This article will provide a detailed step-by-step guide for professionals regarding how to utilize dashboards and key performance indicators (KPIs) to enhance pharmacovigilance monitoring. Understanding US Pharmacovigilance Requirements US pharmacovigilance requirements are primarily governed by the Food and Drug Administration (FDA) regulations, particularly those…

Training US affiliates and partners on FAERS and 21 CFR PV rules Training US affiliates and partners on FAERS and 21 CFR PV rules Introduction to US Pharmacovigilance Requirements Pharmacovigilance (PV) is a critical component of drug safety monitoring, ensuring that the benefits of pharmaceuticals outweigh the risks. In the United States, the Food and Drug Administration (FDA) oversees these activities, particularly through the regulation of adverse event reporting. Among the key systems in place are the FDA Adverse Event Reporting System (FAERS) and the established regulations under 21 CFR 314.80, which mandates postmarketing safety reporting. This article serves as…

Data quality and MedDRA coding expectations for US FAERS submissions Data Quality and MedDRA Coding Expectations for US FAERS Submissions The reporting of adverse events and product complaints plays a critical role in pharmacovigilance, ensuring drug safety for patients within the healthcare system. In the United States, manufacturers must adhere to specific US pharmacovigilance requirements, including the submission of reports to the FDA’s Adverse Event Reporting System (FAERS). This article provides a step-by-step guide on data quality and MedDRA coding expectations for submissions to FAERS, specifically tailored for professionals working in pharmaceuticals, clinical operations, regulatory affairs, and medical affairs. 1….

Aligning REMS, risk evaluation and pharmacovigilance signals in the US Aligning REMS, Risk Evaluation and Pharmacovigilance Signals in the US The management of risks associated with pharmaceutical products is a critical responsibility for companies engaged in drug development and commercialisation. In the United States, the Food and Drug Administration (FDA) provides a comprehensive framework for risk management, which includes the Risk Evaluation and Mitigation Strategies (REMS), postmarketing safety reporting, and pharmacovigilance systems. This tutorial will provide a step-by-step guide on aligning REMS with pharmacovigilance signals, focusing on US pharmacovigilance requirements, particularly FAERS, REMS, and the pertinent sections of 21 CFR…

How to structure a US PV system master file for FDA inspections How to structure a US PV system master file for FDA inspections Pharmacovigilance (PV) is a critical component in ensuring drug safety and efficacy following market approval. This article provides a comprehensive guide to structuring a US Pharmacovigilance (PV) system master file, focusing on key elements required for compliance with FDA inspections. This tutorial is designed for professionals involved in pharmaceutical regulatory affairs, clinical operations, and medical affairs in the US, UK, and EU, with a solid emphasis on adhering to US pharmacovigilance requirements. Understanding the Necessity of…

Future Trends in US Pharmacovigilance Digitalisation and Real World Data Introduction to US Pharmacovigilance Requirements The landscape of pharmacovigilance is continuously evolving, driven by advancements in technology and an increasing emphasis on patient safety. In the United States, pharmacovigilance requirements are governed by a combination of statutory and regulatory frameworks, primarily encapsulated under 21 CFR reporting requirements. These rules outline the processes for monitoring, assessing, and reporting adverse events associated with pharmaceutical products. As we look toward future trends, understanding the pivotal role of digitalisation and real world data (RWD) in enhancing pharmacovigilance systems is crucial. Understanding Key Elements of…

Auditing your US PV system before an FDA safety inspection or PAI Auditing your US PV system before an FDA safety inspection or PAI In the context of pharmaceutical regulation, pharmacovigilance (PV) systems are critical for monitoring the safety of marketed products. With the increasing scrutiny from regulatory agencies, especially the US Food and Drug Administration (FDA), it is essential for pharmaceutical companies to conduct thorough audits of their PV systems. This article will provide a step-by-step tutorial on how to effectively audit your US pharmacovigilance system prior to an FDA safety inspection (either routine or a Pre-Approval Inspection, PAI)….

Third Party Vendor Oversight for FAERS Case Processing and Submissions In the landscape of pharmacovigilance, understanding the nuances of third-party vendor oversight for the FDA Adverse Event Reporting System (FAERS) case processing and submissions is integral for compliance. Regulatory agencies have set forth stringent requirements for post-marketing safety reporting under 21 CFR 314.80. The expectation is that pharmaceutical sponsors ensure quality and compliance in their pharmacovigilance (PV) systems, which includes proper oversight of third-party vendors involved in adverse event case processing. Overview of US Pharmacovigilance Requirements The objective of US pharmacovigilance requirements is to ensure that drug products on the…

PV Quality Metrics that Get Attention in US FDA Safety Inspections Pharmacovigilance (PV) is a critical aspect of drug safety, focusing on the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. To ensure compliance with US pharmacovigilance requirements, it’s essential for pharmaceutical professionals, clinical operations teams, and regulatory affairs experts to understand the various metrics that are scrutinized during safety inspections by the US Food and Drug Administration (FDA). This article serves as a step-by-step tutorial on the key quality metrics and strategies for ensuring compliance with pharmacovigilance regulations such as the FDA Adverse Event…